[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQiXBLSFXp-vCRaHJdP-4YPU1rpScIAvZq3OYFPblezA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"University of Padova",[4,6],"University of Padova, School of Dental Medicine",214,false,37,19,173436,5,164,[15,18,21,24,27,29,31,33],{"name":16,"count":17},"Anesthesia Brain Monitoring",8,{"name":19,"count":20},"Type 2 Diabetes",6,{"name":22,"count":23},"Cirrhosis",4,{"name":25,"count":26},"Anesthesia",3,{"name":28,"count":26},"Quality of Life",{"name":30,"count":26},"Breast Cancer",{"name":32,"count":26},"Type 2 Diabetes Mellitus",{"name":34,"count":26},"Emergence Delirium",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06576700","Effect of Procyanidins in Leaky Gut Repairing in IBD","2025-12-31","Grape Seed Extracts",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05271331","ESP Block Versus Wound Infiltration for Laminectomy","2026-05-20","ESP block with saline",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,84,102,120,138,160,186,210,235,260,285,310,336,369,387,405,429,456,481,507,525,552,570,608,635,653,678,696,720,744,771,789,814,832,859,877,903,929,953,977,1001,1031,1049,1067,1085,1110,1134,1159,1193,1220,1245,1268,1295,1318,1343,1366,1384,1410,1439,1457,1482,1507,1525,1555,1573,1591,1609,1627,1645,1666,1689],{"intervention":45,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":68},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":59},[],{"trials":67,"activeCount":59},[],{"trials":69,"activeCount":55,"soonestReadout":44},[70],{"nctId":42,"briefTitle":43,"status":71,"phases":72,"primaryCompletion":44,"completion":44,"start":73,"enrollment":74,"conditions":75,"interventions":80},"RECRUITING",[52],"2022-05-23",112,[76,77,78,79],"Pain, Postoperative","Opioid Use","Anesthesia, Local","Surgery",[45,81,82,83],"Wound infiltration with saline","ESP block with local anesthetic","Wound infiltration with local anesthetic",{"intervention":81,"totalTrials":55,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":87,"activeCount":59},[],{"trials":89,"activeCount":59},[],{"trials":91,"activeCount":59},[],{"trials":93,"activeCount":59},[],{"trials":95,"activeCount":59},[],{"trials":97,"activeCount":55,"soonestReadout":44},[98],{"nctId":42,"briefTitle":43,"status":71,"phases":99,"primaryCompletion":44,"completion":44,"start":73,"enrollment":74,"conditions":100,"interventions":101},[52],[76,77,78,79],[45,81,82,83],{"intervention":82,"totalTrials":55,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":114},{"trials":105,"activeCount":59},[],{"trials":107,"activeCount":59},[],{"trials":109,"activeCount":59},[],{"trials":111,"activeCount":59},[],{"trials":113,"activeCount":59},[],{"trials":115,"activeCount":55,"soonestReadout":44},[116],{"nctId":42,"briefTitle":43,"status":71,"phases":117,"primaryCompletion":44,"completion":44,"start":73,"enrollment":74,"conditions":118,"interventions":119},[52],[76,77,78,79],[45,81,82,83],{"intervention":83,"totalTrials":55,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":132},{"trials":123,"activeCount":59},[],{"trials":125,"activeCount":59},[],{"trials":127,"activeCount":59},[],{"trials":129,"activeCount":59},[],{"trials":131,"activeCount":59},[],{"trials":133,"activeCount":55,"soonestReadout":44},[134],{"nctId":42,"briefTitle":43,"status":71,"phases":135,"primaryCompletion":44,"completion":44,"start":73,"enrollment":74,"conditions":136,"interventions":137},[52],[76,77,78,79],[45,81,82,83],{"intervention":40,"totalTrials":55,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":150},{"trials":141,"activeCount":59},[],{"trials":143,"activeCount":59},[],{"trials":145,"activeCount":59},[],{"trials":147,"activeCount":59},[],{"trials":149,"activeCount":59},[],{"trials":151,"activeCount":55,"soonestReadout":39},[152],{"nctId":37,"briefTitle":38,"status":71,"phases":153,"primaryCompletion":39,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},[52],"2026-06-12","2024-06-15",25,[158],"Ulcerative Colitis in Remission",[40],{"intervention":161,"totalTrials":55,"cells":162},"Filgrastim, hrG-CSF",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":184},{"trials":164,"activeCount":59},[],{"trials":166,"activeCount":59},[],{"trials":168,"activeCount":59},[],{"trials":170,"activeCount":59},[],{"trials":172,"activeCount":59},[173],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT01102699","Bone Marrow Progenitor Cell Mobilization in Diabetes","COMPLETED",[51],"2013-08","2010-06",48,[182],"Diabetes Mellitus",[161],{"trials":185,"activeCount":59},[],{"intervention":187,"totalTrials":55,"cells":188},"Sitagliptin",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":208},{"trials":190,"activeCount":59},[],{"trials":192,"activeCount":59},[],{"trials":194,"activeCount":59},[],{"trials":196,"activeCount":59},[],{"trials":198,"activeCount":59},[199],{"nctId":200,"briefTitle":201,"status":176,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT00968006","Effect of Sitagliptin on Endothelial Progenitor Cells",[51],"2010-01","2009-10",40,[32],[187],{"trials":209,"activeCount":59},[],{"intervention":211,"totalTrials":55,"cells":212},"Spironolactone and furosemide",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":233},{"trials":214,"activeCount":59},[],{"trials":216,"activeCount":59},[],{"trials":218,"activeCount":59},[],{"trials":220,"activeCount":59},[],{"trials":222,"activeCount":59},[223],{"nctId":224,"briefTitle":225,"status":176,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT00741663","Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)",[51],"2008-09","2005-04",100,[22,231],"Ascites",[211,211],{"trials":234,"activeCount":59},[],{"intervention":236,"totalTrials":55,"cells":237},"Linagliptin",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":258},{"trials":239,"activeCount":59},[],{"trials":241,"activeCount":59},[],{"trials":243,"activeCount":59},[],{"trials":245,"activeCount":59},[],{"trials":247,"activeCount":59},[248],{"nctId":249,"briefTitle":250,"status":176,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT01617824","Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes",[51],"2014-12","2012-09",45,[19,256],"Chronic Renal Failure",[236],{"trials":259,"activeCount":59},[],{"intervention":261,"totalTrials":55,"cells":262},"Mozobil",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":283},{"trials":264,"activeCount":59},[],{"trials":266,"activeCount":59},[],{"trials":268,"activeCount":59},[],{"trials":270,"activeCount":59},[],{"trials":272,"activeCount":59},[273],{"nctId":274,"briefTitle":275,"status":176,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},"NCT02056210","Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects",[51],"2014-10","2014-02",20,[281],"Diabetes",[261],{"trials":284,"activeCount":59},[],{"intervention":286,"totalTrials":55,"cells":287},"Atorvastatin",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":308},{"trials":289,"activeCount":59},[],{"trials":291,"activeCount":59},[],{"trials":293,"activeCount":59},[],{"trials":295,"activeCount":59},[],{"trials":297,"activeCount":59},[298],{"nctId":299,"briefTitle":300,"status":176,"phases":301,"primaryCompletion":278,"completion":302,"start":303,"enrollment":279,"conditions":304,"interventions":307},"NCT02342015","Effect of Atorvastatin on Bone-vascular Axis",[51],"2014-03","2012-11",[305,306],"Osteoporosis","Hypercholesterolemia",[286],{"trials":309,"activeCount":59},[],{"intervention":311,"totalTrials":55,"cells":312},"antibiotic to reduce the recurrence of infection",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":314,"activeCount":59},[],{"trials":316,"activeCount":59},[],{"trials":318,"activeCount":59},[],{"trials":320,"activeCount":59},[],{"trials":322,"activeCount":59},[323],{"nctId":324,"briefTitle":325,"status":326,"phases":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT00156546","Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection","UNKNOWN",[51],"2006-07","2000-05",660,[332],"Urinary Tract Infections",[311],{"trials":335,"activeCount":59},[],{"intervention":337,"totalTrials":55,"cells":338},"Sucrosomial iron",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":367},{"trials":340,"activeCount":59},[],{"trials":342,"activeCount":59},[],{"trials":344,"activeCount":59},[],{"trials":346,"activeCount":59},[],{"trials":348,"activeCount":59},[349],{"nctId":350,"briefTitle":351,"status":326,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":364},"NCT05702970","Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency",[51],"2025-04-01","2025-10-31","2024-01-15",258,[358,359,360,361,362,363],"Heart Failure","Iron-deficiency","Heart Failure, Systolic","Heart Failure NYHA Class II","Heart Failure NYHA Class III","Vitamin D Deficiency",[337,365,366],"Vitamin D","Ferric Carboxymaltose 50 MG\u002FML",{"trials":368,"activeCount":59},[],{"intervention":365,"totalTrials":55,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":385},{"trials":372,"activeCount":59},[],{"trials":374,"activeCount":59},[],{"trials":376,"activeCount":59},[],{"trials":378,"activeCount":59},[],{"trials":380,"activeCount":59},[381],{"nctId":350,"briefTitle":351,"status":326,"phases":382,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":383,"interventions":384},[51],[358,359,360,361,362,363],[337,365,366],{"trials":386,"activeCount":59},[],{"intervention":366,"totalTrials":55,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":403},{"trials":390,"activeCount":59},[],{"trials":392,"activeCount":59},[],{"trials":394,"activeCount":59},[],{"trials":396,"activeCount":59},[],{"trials":398,"activeCount":59},[399],{"nctId":350,"briefTitle":351,"status":326,"phases":400,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":401,"interventions":402},[51],[358,359,360,361,362,363],[337,365,366],{"trials":404,"activeCount":59},[],{"intervention":406,"totalTrials":55,"cells":407},"Adalimumab, etanercept, infliximab",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":427},{"trials":409,"activeCount":59},[],{"trials":411,"activeCount":59},[],{"trials":413,"activeCount":59},[],{"trials":415,"activeCount":59},[],{"trials":417,"activeCount":59},[418],{"nctId":419,"briefTitle":420,"status":326,"phases":421,"primaryCompletion":422,"start":422,"enrollment":279,"conditions":423,"interventions":426},"NCT01237262","Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy",[51],"2010-11",[424,425],"Moderate to Severe Psoriasis.","Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.",[406],{"trials":428,"activeCount":59},[],{"intervention":430,"totalTrials":55,"cells":431},"Metformin",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":454},{"trials":433,"activeCount":59},[],{"trials":435,"activeCount":59},[],{"trials":437,"activeCount":59},[],{"trials":439,"activeCount":59},[],{"trials":441,"activeCount":59},[442],{"nctId":443,"briefTitle":444,"status":176,"phases":445,"primaryCompletion":446,"completion":446,"start":179,"enrollment":447,"conditions":448,"interventions":453},"NCT01765946","Metformin and Longevity Genes in Prediabetes",[51],"2013-03",38,[449,450,451,452],"Insulin Resistance","Prediabetes","Aging","Inflammation",[430],{"trials":455,"activeCount":59},[],{"intervention":457,"totalTrials":55,"cells":458},"Fenofibrate 145 mg",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":479},{"trials":460,"activeCount":59},[],{"trials":462,"activeCount":59},[],{"trials":464,"activeCount":59},[],{"trials":466,"activeCount":59},[],{"trials":468,"activeCount":59},[469],{"nctId":470,"briefTitle":471,"status":176,"phases":472,"primaryCompletion":473,"completion":474,"start":178,"enrollment":475,"conditions":476,"interventions":478},"NCT01927315","Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes",[51],"2019-10","2019-12",41,[281,477],"Diabetic Retinopathy",[457],{"trials":480,"activeCount":59},[],{"intervention":482,"totalTrials":55,"cells":483},"Lattoferrin",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":505},{"trials":485,"activeCount":59},[],{"trials":487,"activeCount":59},[],{"trials":489,"activeCount":59},[],{"trials":491,"activeCount":59},[],{"trials":493,"activeCount":59},[494],{"nctId":495,"briefTitle":496,"status":326,"phases":497,"primaryCompletion":498,"completion":499,"start":278,"enrollment":500,"conditions":501,"interventions":503},"NCT02372942","Lactoferrin or Progesterone for Prevention of Preterm Delivery",[51],"2019-11","2020-12",1030,[502],"Preterm Delivery",[482,504],"Progesterone",{"trials":506,"activeCount":59},[],{"intervention":504,"totalTrials":55,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":523},{"trials":510,"activeCount":59},[],{"trials":512,"activeCount":59},[],{"trials":514,"activeCount":59},[],{"trials":516,"activeCount":59},[],{"trials":518,"activeCount":59},[519],{"nctId":495,"briefTitle":496,"status":326,"phases":520,"primaryCompletion":498,"completion":499,"start":278,"enrollment":500,"conditions":521,"interventions":522},[51],[502],[482,504],{"trials":524,"activeCount":59},[],{"intervention":526,"totalTrials":55,"cells":527},"Glargine",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":550},{"trials":529,"activeCount":59},[],{"trials":531,"activeCount":59},[],{"trials":533,"activeCount":59},[],{"trials":535,"activeCount":59},[],{"trials":537,"activeCount":59},[538],{"nctId":539,"briefTitle":540,"status":176,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":548},"NCT00699686","Endothelial Effects of Basal Insulin: Detemir Versus Glargine",[51],"2010-03","2008-05",50,[19,546,547],"Endothelial Dysfunction","Cardiovascular Disease",[526,549],"Detemir",{"trials":551,"activeCount":59},[],{"intervention":549,"totalTrials":55,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":59},[],{"trials":557,"activeCount":59},[],{"trials":559,"activeCount":59},[],{"trials":561,"activeCount":59},[],{"trials":563,"activeCount":59},[564],{"nctId":539,"briefTitle":540,"status":176,"phases":565,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":566,"interventions":567},[51],[19,546,547],[526,549],{"trials":569,"activeCount":59},[],{"intervention":571,"totalTrials":572,"cells":573},"sodium warfarin",2,{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":604,"NA":606},{"trials":575,"activeCount":59},[],{"trials":577,"activeCount":59},[],{"trials":579,"activeCount":59},[],{"trials":581,"activeCount":59},[582,594],{"nctId":583,"briefTitle":584,"status":176,"phases":585,"primaryCompletion":586,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT00380120","Ultrasound Findings to Adjust the Duration of Anticoagulation",[50],"2003-06","2006-06","1999-01",538,[591],"Deep Vein Thrombosis",[571,593],"Sodium warfarin",{"nctId":595,"briefTitle":596,"status":176,"phases":597,"primaryCompletion":598,"completion":598,"start":542,"enrollment":599,"conditions":600,"interventions":603},"NCT01285661","Optimal Duration of Anticoagulation in Deep Venous Thrombosis",[50],"2015-10",584,[601,602],"Deep Vein Thrombosis of Lower Limb","Lower Extremity Deep Venous Thrombosis Recurrent",[593],{"trials":605,"activeCount":59},[],{"trials":607,"activeCount":59},[],{"intervention":609,"totalTrials":55,"cells":610},"Terlipressin plus albumin",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":631,"NA":633},{"trials":612,"activeCount":59},[],{"trials":614,"activeCount":59},[],{"trials":616,"activeCount":59},[],{"trials":618,"activeCount":59},[619],{"nctId":620,"briefTitle":621,"status":622,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT00742339","Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome","TERMINATED",[49,50],"2013-10","2005-05",49,[22,628],"Hepatorenal Syndrome",[609,630],"Midodrine plus octreotide plus human albumin",{"trials":632,"activeCount":59},[],{"trials":634,"activeCount":59},[],{"intervention":630,"totalTrials":55,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":649,"NA":651},{"trials":638,"activeCount":59},[],{"trials":640,"activeCount":59},[],{"trials":642,"activeCount":59},[],{"trials":644,"activeCount":59},[645],{"nctId":620,"briefTitle":621,"status":622,"phases":646,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":647,"interventions":648},[49,50],[22,628],[609,630],{"trials":650,"activeCount":59},[],{"trials":652,"activeCount":59},[],{"intervention":654,"totalTrials":55,"cells":655},"oral amoxicilline\u002Fclavulanic acid",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":674,"NA":676},{"trials":657,"activeCount":59},[],{"trials":659,"activeCount":59},[],{"trials":661,"activeCount":59},[],{"trials":663,"activeCount":59},[664],{"nctId":665,"briefTitle":666,"status":622,"phases":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":672},"NCT00161330","Oral vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT",[50],"2005-07","2000-06",440,[332],[654,673],"iv ceftriaxone",{"trials":675,"activeCount":59},[],{"trials":677,"activeCount":59},[],{"intervention":673,"totalTrials":55,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":692,"NA":694},{"trials":681,"activeCount":59},[],{"trials":683,"activeCount":59},[],{"trials":685,"activeCount":59},[],{"trials":687,"activeCount":59},[688],{"nctId":665,"briefTitle":666,"status":622,"phases":689,"completion":668,"start":669,"enrollment":670,"conditions":690,"interventions":691},[50],[332],[654,673],{"trials":693,"activeCount":59},[],{"trials":695,"activeCount":59},[],{"intervention":697,"totalTrials":55,"cells":698},"Experimental: Rivaroxaban",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":716,"NA":718},{"trials":700,"activeCount":59},[],{"trials":702,"activeCount":59},[],{"trials":704,"activeCount":59},[],{"trials":706,"activeCount":59},[707],{"nctId":708,"briefTitle":709,"status":622,"phases":710,"primaryCompletion":711,"completion":711,"start":252,"enrollment":712,"conditions":713,"interventions":715},"NCT02157272","Rivaroxaban in Thrombotic Antiphospholipid Syndrome",[50],"2018-01-25",121,[714],"Antiphospholipid Syndrome",[697],{"trials":717,"activeCount":59},[],{"trials":719,"activeCount":59},[],{"intervention":721,"totalTrials":55,"cells":722},"propranolol",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":740,"NA":742},{"trials":724,"activeCount":59},[],{"trials":726,"activeCount":59},[],{"trials":728,"activeCount":59},[],{"trials":730,"activeCount":59},[731],{"nctId":732,"briefTitle":733,"status":622,"phases":734,"enrollment":735,"conditions":736,"interventions":739},"NCT00337740","Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding",[50],120,[737,738],"Liver Cirrhosis","Esophageal Varices",[721],{"trials":741,"activeCount":59},[],{"trials":743,"activeCount":59},[],{"intervention":745,"totalTrials":55,"cells":746},"Daptomycin + Meropenem",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":767,"NA":769},{"trials":748,"activeCount":59},[],{"trials":750,"activeCount":59},[],{"trials":752,"activeCount":59},[],{"trials":754,"activeCount":59},[755],{"nctId":756,"briefTitle":757,"status":622,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT01455246","Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis",[49,50],"2014-04","2014-07","2010-10",32,[22,231,764],"Nosocomial Spontaneous Bacterial Peritonitis",[745,766],"Ceftazidime",{"trials":768,"activeCount":59},[],{"trials":770,"activeCount":59},[],{"intervention":766,"totalTrials":55,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":785,"NA":787},{"trials":774,"activeCount":59},[],{"trials":776,"activeCount":59},[],{"trials":778,"activeCount":59},[],{"trials":780,"activeCount":59},[781],{"nctId":756,"briefTitle":757,"status":622,"phases":782,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":783,"interventions":784},[49,50],[22,231,764],[745,766],{"trials":786,"activeCount":59},[],{"trials":788,"activeCount":59},[],{"intervention":790,"totalTrials":55,"cells":791},"terlipressin given by intravenous boluses and albumin",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":810,"NA":812},{"trials":793,"activeCount":59},[],{"trials":795,"activeCount":59},[],{"trials":797,"activeCount":59},[],{"trials":799,"activeCount":59},[800],{"nctId":801,"briefTitle":802,"status":326,"phases":803,"primaryCompletion":252,"completion":804,"start":625,"enrollment":805,"conditions":806,"interventions":808},"NCT00742690","Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome",[49,50],"2015-03",70,[22,807],"Type 1 Hepatorenal Syndrome",[790,809],"terlipressin given by continuous intravenous infusion and albumin",{"trials":811,"activeCount":59},[],{"trials":813,"activeCount":59},[],{"intervention":809,"totalTrials":55,"cells":815},{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":828,"NA":830},{"trials":817,"activeCount":59},[],{"trials":819,"activeCount":59},[],{"trials":821,"activeCount":59},[],{"trials":823,"activeCount":59},[824],{"nctId":801,"briefTitle":802,"status":326,"phases":825,"primaryCompletion":252,"completion":804,"start":625,"enrollment":805,"conditions":826,"interventions":827},[49,50],[22,807],[790,809],{"trials":829,"activeCount":59},[],{"trials":831,"activeCount":59},[],{"intervention":833,"totalTrials":55,"cells":834},"Intravenous paracetamol",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":855,"NA":857},{"trials":836,"activeCount":59},[],{"trials":838,"activeCount":59},[],{"trials":840,"activeCount":59},[],{"trials":842,"activeCount":59},[843],{"nctId":844,"briefTitle":845,"status":846,"phases":847,"primaryCompletion":848,"completion":848,"start":849,"enrollment":735,"conditions":850,"interventions":853},"NCT02056223","Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.","SUSPENDED",[49,50],"2019-10-31","2017-01-09",[851,852],"Ductus Arteriosus Patent","Respiratory Distress Syndrome",[833,854],"Intravenous ibuprofen",{"trials":856,"activeCount":59},[],{"trials":858,"activeCount":59},[],{"intervention":854,"totalTrials":55,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":873,"NA":875},{"trials":862,"activeCount":59},[],{"trials":864,"activeCount":59},[],{"trials":866,"activeCount":59},[],{"trials":868,"activeCount":59},[869],{"nctId":844,"briefTitle":845,"status":846,"phases":870,"primaryCompletion":848,"completion":848,"start":849,"enrollment":735,"conditions":871,"interventions":872},[49,50],[851,852],[833,854],{"trials":874,"activeCount":59},[],{"trials":876,"activeCount":59},[],{"intervention":878,"totalTrials":55,"cells":879},"fentanyl",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":899,"NA":901},{"trials":881,"activeCount":59},[],{"trials":883,"activeCount":59},[],{"trials":885,"activeCount":59},[],{"trials":887,"activeCount":59},[888],{"nctId":889,"briefTitle":890,"status":326,"phases":891,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":895,"interventions":897},"NCT01724983","Ketamine in Bariatric Surgery",[50],"2014-06","2012-06",90,[896],"Morbid Obesity",[898,878],"ketamine",{"trials":900,"activeCount":59},[],{"trials":902,"activeCount":59},[],{"intervention":904,"totalTrials":55,"cells":905},"Rifaximin",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":925,"NA":927},{"trials":907,"activeCount":59},[],{"trials":909,"activeCount":59},[],{"trials":911,"activeCount":59},[],{"trials":913,"activeCount":59},[914],{"nctId":915,"briefTitle":916,"status":326,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT02508623","Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices",[50],"2017-01","2017-07","2015-07",60,[737,923],"Portal Hypertension",[904],{"trials":926,"activeCount":59},[],{"trials":928,"activeCount":59},[],{"intervention":930,"totalTrials":55,"cells":931},"Ropivacaine",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":949,"NA":951},{"trials":933,"activeCount":59},[],{"trials":935,"activeCount":59},[],{"trials":937,"activeCount":59},[],{"trials":939,"activeCount":59},[940],{"nctId":941,"briefTitle":942,"status":326,"phases":943,"primaryCompletion":253,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT01623635","Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery",[50],"2012-02",200,[947],"Postoperative Pain",[930],{"trials":950,"activeCount":59},[],{"trials":952,"activeCount":59},[],{"intervention":954,"totalTrials":55,"cells":955},"Calculate warfarin dose using demographic\u002Fgenetic algorithm",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":973,"NA":975},{"trials":957,"activeCount":59},[],{"trials":959,"activeCount":59},[],{"trials":961,"activeCount":59},[],{"trials":963,"activeCount":59},[964],{"nctId":965,"briefTitle":966,"status":176,"phases":967,"primaryCompletion":968,"completion":968,"start":204,"enrollment":969,"conditions":970,"interventions":972},"NCT01178034","Early Identification of Warfarin Maintenance Dosage",[50],"2012-10",180,[971],"Atrial Fibrillation",[954],{"trials":974,"activeCount":59},[],{"trials":976,"activeCount":59},[],{"intervention":978,"totalTrials":55,"cells":979},"Deproteinized bovine bone",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":981,"activeCount":59},[],{"trials":983,"activeCount":59},[],{"trials":985,"activeCount":59},[986],{"nctId":987,"briefTitle":988,"status":176,"phases":989,"primaryCompletion":252,"completion":990,"start":991,"enrollment":279,"conditions":992,"interventions":994},"NCT02612740","Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal",[49],"2016-10","2010-04",[993],"Maxillary Cyst",[978],{"trials":996,"activeCount":59},[],{"trials":998,"activeCount":59},[],{"trials":1000,"activeCount":59},[],{"intervention":1002,"totalTrials":55,"cells":1003},"L-HBO",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1025,"PHASE4":1027,"NA":1029},{"trials":1005,"activeCount":59},[],{"trials":1007,"activeCount":59},[],{"trials":1009,"activeCount":59},[1010],{"nctId":1011,"briefTitle":1012,"status":176,"phases":1013,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1021},"NCT04366427","Enriched Oxygen Mixtures in Athletes",[49],"2020-11-15","2020-12-31","2020-09-15",42,[1019,1020],"Oxidative Stress","Stem Cell Research",[1002,1022,1023,1024],"HBO","30% O2","50% O2",{"trials":1026,"activeCount":59},[],{"trials":1028,"activeCount":59},[],{"trials":1030,"activeCount":59},[],{"intervention":1022,"totalTrials":55,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1034,"activeCount":59},[],{"trials":1036,"activeCount":59},[],{"trials":1038,"activeCount":59},[1039],{"nctId":1011,"briefTitle":1012,"status":176,"phases":1040,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1041,"interventions":1042},[49],[1019,1020],[1002,1022,1023,1024],{"trials":1044,"activeCount":59},[],{"trials":1046,"activeCount":59},[],{"trials":1048,"activeCount":59},[],{"intervention":1023,"totalTrials":55,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1052,"activeCount":59},[],{"trials":1054,"activeCount":59},[],{"trials":1056,"activeCount":59},[1057],{"nctId":1011,"briefTitle":1012,"status":176,"phases":1058,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1059,"interventions":1060},[49],[1019,1020],[1002,1022,1023,1024],{"trials":1062,"activeCount":59},[],{"trials":1064,"activeCount":59},[],{"trials":1066,"activeCount":59},[],{"intervention":1024,"totalTrials":55,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1070,"activeCount":59},[],{"trials":1072,"activeCount":59},[],{"trials":1074,"activeCount":59},[1075],{"nctId":1011,"briefTitle":1012,"status":176,"phases":1076,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1077,"interventions":1078},[49],[1019,1020],[1002,1022,1023,1024],{"trials":1080,"activeCount":59},[],{"trials":1082,"activeCount":59},[],{"trials":1084,"activeCount":59},[],{"intervention":1086,"totalTrials":55,"cells":1087},"Rivaroxaban",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1089,"activeCount":59},[],{"trials":1091,"activeCount":59},[],{"trials":1093,"activeCount":59},[1094],{"nctId":1095,"briefTitle":1096,"status":176,"phases":1097,"primaryCompletion":302,"completion":302,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1103},"NCT01629381","Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy",[49],"2012-05",500,[1101,1102],"Venous Thromboembolism","Haemorrhage",[1086],{"trials":1105,"activeCount":59},[],{"trials":1107,"activeCount":59},[],{"trials":1109,"activeCount":59},[],{"intervention":1111,"totalTrials":55,"cells":1112},"etanercept",{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1128,"PHASE4":1130,"NA":1132},{"trials":1114,"activeCount":59},[],{"trials":1116,"activeCount":59},[],{"trials":1118,"activeCount":59},[1119],{"nctId":1120,"briefTitle":1121,"status":176,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":228,"enrollment":1124,"conditions":1125,"interventions":1127},"NCT00678782","Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis",[49],"2007-12",31,[1126],"Persistent Knee Joint Synovitis",[1111],{"trials":1129,"activeCount":59},[],{"trials":1131,"activeCount":59},[],{"trials":1133,"activeCount":59},[],{"intervention":1135,"totalTrials":55,"cells":1136},"Bevacizumab",{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1153,"PHASE4":1155,"NA":1157},{"trials":1138,"activeCount":59},[],{"trials":1140,"activeCount":59},[],{"trials":1142,"activeCount":59},[1143],{"nctId":1144,"briefTitle":1145,"status":1146,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":59,"conditions":1150,"interventions":1152},"NCT00696592","Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration","WITHDRAWN",[49],"2008-01-31","2007-01-31",[1151],"Neovascular Age-related Macular Degeneration",[1135],{"trials":1154,"activeCount":59},[],{"trials":1156,"activeCount":59},[],{"trials":1158,"activeCount":59},[],{"intervention":1160,"totalTrials":572,"cells":1161},"Dapagliflozin",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1170,"NA":1180},{"trials":1163,"activeCount":59},[],{"trials":1165,"activeCount":59},[],{"trials":1167,"activeCount":59},[],{"trials":1169,"activeCount":59},[],{"trials":1171,"activeCount":59},[1172],{"nctId":1173,"briefTitle":1174,"status":176,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":804,"enrollment":1177,"conditions":1178,"interventions":1179},"NCT02327039","The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients",[51],"2016-09",33,[19],[1160],{"trials":1181,"activeCount":59},[1182],{"nctId":1183,"briefTitle":1184,"status":176,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1191},"NCT04304430","Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors",[],"2019-12-26","2020-02-29","2018-10-18",11206,[19],[1160,1192],"DPP-4 inhibitor",{"intervention":1194,"totalTrials":572,"cells":1195},"Ketamine",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1208,"NA":1210},{"trials":1197,"activeCount":59},[],{"trials":1199,"activeCount":59},[],{"trials":1201,"activeCount":59},[],{"trials":1203,"activeCount":59},[1204],{"nctId":889,"briefTitle":890,"status":326,"phases":1205,"primaryCompletion":892,"completion":892,"start":893,"enrollment":894,"conditions":1206,"interventions":1207},[50],[896],[898,878],{"trials":1209,"activeCount":59},[],{"trials":1211,"activeCount":59},[1212],{"nctId":1213,"briefTitle":1214,"status":176,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":205,"conditions":1218,"interventions":1219},"NCT05799729","Effect of Ketamine Infusion on BIS Values",[],"2023-09-30","2023-04-01",[16,1194],[1194],{"intervention":1221,"totalTrials":55,"cells":1222},"Injection of 1-13 Carbon Leucine and deuterated water",{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1224,"activeCount":59},[],{"trials":1226,"activeCount":59},[],{"trials":1228,"activeCount":59},[],{"trials":1230,"activeCount":59},[],{"trials":1232,"activeCount":59},[],{"trials":1234,"activeCount":59},[1235],{"nctId":1236,"briefTitle":1237,"status":176,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":761,"enrollment":1240,"conditions":1241,"interventions":1244},"NCT03371680","Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU)",[52],"2013-12-31",21,[1242,1243],"ARDS","Sepsis Syndrome",[1221],{"intervention":1246,"totalTrials":55,"cells":1247},"Dexmedetomidine",{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1249,"activeCount":59},[],{"trials":1251,"activeCount":59},[],{"trials":1253,"activeCount":59},[],{"trials":1255,"activeCount":59},[],{"trials":1257,"activeCount":59},[],{"trials":1259,"activeCount":59},[1260],{"nctId":1261,"briefTitle":1262,"status":326,"phases":1263,"primaryCompletion":1217,"completion":1217,"start":1264,"enrollment":205,"conditions":1265,"interventions":1267},"NCT04820101","Dexmedetomidine for LISA Procedure in Preterm Infants",[52],"2021-05-15",[1266],"RDS",[1246],{"intervention":1269,"totalTrials":55,"cells":1270},"Local anesthetic",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1272,"activeCount":59},[],{"trials":1274,"activeCount":59},[],{"trials":1276,"activeCount":59},[],{"trials":1278,"activeCount":59},[],{"trials":1280,"activeCount":59},[],{"trials":1282,"activeCount":59},[1283],{"nctId":1284,"briefTitle":1285,"status":176,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1294},"NCT06121726","Predictive Factors for the Effectiveness of the Ilioinguinal Iliohypogastric Nerve Block for Hernia Surgery",[],"2025-05-02","2023-10-13",343,[1291,1292,1293],"Hernia Inguinal","Pain Postoperative","Regional Anesthesia",[1269],{"intervention":1296,"totalTrials":55,"cells":1297},"Analgesic Therapy",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1299,"activeCount":59},[],{"trials":1301,"activeCount":59},[],{"trials":1303,"activeCount":59},[],{"trials":1305,"activeCount":59},[],{"trials":1307,"activeCount":59},[],{"trials":1309,"activeCount":59},[1310],{"nctId":1311,"briefTitle":1312,"status":176,"phases":1313,"primaryCompletion":892,"completion":892,"start":1314,"enrollment":544,"conditions":1315,"interventions":1317},"NCT02269748","Morbidity and Coverage Outcome With Connective Tissue Graft Used With Coronally Advanced Flap and Tunneling Technique",[52],"2012-04",[1316],"Gingival Recession",[1296],{"intervention":1319,"totalTrials":55,"cells":1320},"Aminophyllin",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1331},{"trials":1322,"activeCount":59},[],{"trials":1324,"activeCount":59},[],{"trials":1326,"activeCount":59},[],{"trials":1328,"activeCount":59},[],{"trials":1330,"activeCount":59},[],{"trials":1332,"activeCount":59},[1333],{"nctId":1334,"briefTitle":1335,"status":176,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":180,"conditions":1340,"interventions":1342},"NCT06098196","Effects of Aminophylline Bolus on TCI (Target Controlled Infusion) Concentrations at Return of Responsiveness",[],"2024-02-28","2024-03-15","2023-10-25",[1341,16],"Propofol",[1319],{"intervention":1344,"totalTrials":55,"cells":1345},"Rocuronium",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1347,"activeCount":59},[],{"trials":1349,"activeCount":59},[],{"trials":1351,"activeCount":59},[],{"trials":1353,"activeCount":59},[],{"trials":1355,"activeCount":59},[],{"trials":1357,"activeCount":59},[1358],{"nctId":1359,"briefTitle":1360,"status":176,"phases":1361,"primaryCompletion":1216,"completion":1216,"start":1362,"enrollment":17,"conditions":1363,"interventions":1365},"NCT05681611","Effect of Rocuronium on BIS Values",[],"2023-03-03",[30,1364],"General Anaesthesia",[1344],{"intervention":1192,"totalTrials":55,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1369,"activeCount":59},[],{"trials":1371,"activeCount":59},[],{"trials":1373,"activeCount":59},[],{"trials":1375,"activeCount":59},[],{"trials":1377,"activeCount":59},[],{"trials":1379,"activeCount":59},[1380],{"nctId":1183,"briefTitle":1184,"status":176,"phases":1381,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1382,"interventions":1383},[],[19],[1160,1192],{"intervention":1385,"totalTrials":55,"cells":1386},"Insulin degludec",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1388,"activeCount":59},[],{"trials":1390,"activeCount":59},[],{"trials":1392,"activeCount":59},[],{"trials":1394,"activeCount":59},[],{"trials":1396,"activeCount":59},[],{"trials":1398,"activeCount":59},[1399],{"nctId":1400,"briefTitle":1401,"status":176,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT02360254","Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes",[],"2016-01","2016-02","2015-01",26,[1408],"Type 1 Diabetes Mellitus",[1385],{"intervention":1411,"totalTrials":55,"cells":1412},"Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1414,"activeCount":59},[],{"trials":1416,"activeCount":59},[],{"trials":1418,"activeCount":59},[],{"trials":1420,"activeCount":59},[],{"trials":1422,"activeCount":59},[],{"trials":1424,"activeCount":59},[1425],{"nctId":1426,"briefTitle":1427,"status":176,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1437},"NCT05478941","Can Virtual Reality Improve the Progressive Muscular Relaxation Technique Efficacy?",[52],"2023-07-24","2022-02-08",150,[1433,1434,1435,1436,28],"Anxiety","Coping Skills","Depression","Stress, Emotional",[1411,1438],"Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).",{"intervention":1438,"totalTrials":55,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1442,"activeCount":59},[],{"trials":1444,"activeCount":59},[],{"trials":1446,"activeCount":59},[],{"trials":1448,"activeCount":59},[],{"trials":1450,"activeCount":59},[],{"trials":1452,"activeCount":59},[1453],{"nctId":1426,"briefTitle":1427,"status":176,"phases":1454,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1455,"interventions":1456},[52],[1433,1434,1435,1436,28],[1411,1438],{"intervention":1458,"totalTrials":55,"cells":1459},"We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1461,"activeCount":59},[],{"trials":1463,"activeCount":59},[],{"trials":1465,"activeCount":59},[],{"trials":1467,"activeCount":59},[],{"trials":1469,"activeCount":59},[],{"trials":1471,"activeCount":59},[1472],{"nctId":1473,"briefTitle":1474,"status":176,"phases":1475,"primaryCompletion":1476,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1481},"NCT04129112","Evaluation of Influencing Variables in Awakening Concentration and Concentration at Body Movements of Propofol TCI (Targeted Controlled Infusion) Targeted at the Effector Site",[],"2019-12-15","2019-07-01",75,[1480],"Awareness, Anesthesia",[1458],{"intervention":1483,"totalTrials":55,"cells":1484},"SGLT2 inhibitor",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1486,"activeCount":59},[],{"trials":1488,"activeCount":59},[],{"trials":1490,"activeCount":59},[],{"trials":1492,"activeCount":59},[],{"trials":1494,"activeCount":59},[],{"trials":1496,"activeCount":59},[1497],{"nctId":1498,"briefTitle":1499,"status":176,"phases":1500,"primaryCompletion":1501,"completion":1187,"start":1502,"enrollment":1503,"conditions":1504,"interventions":1505},"NCT04184947","Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists",[],"2018-12-31","2014-03-01",10000,[19],[1483,1506],"GLP-1 receptor agonist",{"intervention":1506,"totalTrials":55,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1510,"activeCount":59},[],{"trials":1512,"activeCount":59},[],{"trials":1514,"activeCount":59},[],{"trials":1516,"activeCount":59},[],{"trials":1518,"activeCount":59},[],{"trials":1520,"activeCount":59},[1521],{"nctId":1498,"briefTitle":1499,"status":176,"phases":1522,"primaryCompletion":1501,"completion":1187,"start":1502,"enrollment":1503,"conditions":1523,"interventions":1524},[],[19],[1483,1506],{"intervention":1526,"totalTrials":55,"cells":1527},"Long-acting GLP-1RA",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1529,"activeCount":59},[],{"trials":1531,"activeCount":59},[],{"trials":1533,"activeCount":59},[],{"trials":1535,"activeCount":59},[],{"trials":1537,"activeCount":59},[],{"trials":1539,"activeCount":59},[1540],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1543,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1549},"NCT03959865","GLP-1 REceptor Agonists and Real World EvIdeNce",[],"2019-02-11","2019-05-31","2018-12-19",6000,[19],[1526,1550,1551,1552,1553,1554],"Short-acting GLP-1RA","Human-based GLP-1RA","Exendin-based GLP-1RA","Fixed ratio BI\u002FGLP-1RA combination","Flexible BI\u002FGLP-1RA combination",{"intervention":1550,"totalTrials":55,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1558,"activeCount":59},[],{"trials":1560,"activeCount":59},[],{"trials":1562,"activeCount":59},[],{"trials":1564,"activeCount":59},[],{"trials":1566,"activeCount":59},[],{"trials":1568,"activeCount":59},[1569],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1570,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1571,"interventions":1572},[],[19],[1526,1550,1551,1552,1553,1554],{"intervention":1551,"totalTrials":55,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1576,"activeCount":59},[],{"trials":1578,"activeCount":59},[],{"trials":1580,"activeCount":59},[],{"trials":1582,"activeCount":59},[],{"trials":1584,"activeCount":59},[],{"trials":1586,"activeCount":59},[1587],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1588,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1589,"interventions":1590},[],[19],[1526,1550,1551,1552,1553,1554],{"intervention":1552,"totalTrials":55,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1594,"activeCount":59},[],{"trials":1596,"activeCount":59},[],{"trials":1598,"activeCount":59},[],{"trials":1600,"activeCount":59},[],{"trials":1602,"activeCount":59},[],{"trials":1604,"activeCount":59},[1605],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1606,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1607,"interventions":1608},[],[19],[1526,1550,1551,1552,1553,1554],{"intervention":1553,"totalTrials":55,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1612,"activeCount":59},[],{"trials":1614,"activeCount":59},[],{"trials":1616,"activeCount":59},[],{"trials":1618,"activeCount":59},[],{"trials":1620,"activeCount":59},[],{"trials":1622,"activeCount":59},[1623],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1624,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1625,"interventions":1626},[],[19],[1526,1550,1551,1552,1553,1554],{"intervention":1554,"totalTrials":55,"cells":1628},{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1630,"activeCount":59},[],{"trials":1632,"activeCount":59},[],{"trials":1634,"activeCount":59},[],{"trials":1636,"activeCount":59},[],{"trials":1638,"activeCount":59},[],{"trials":1640,"activeCount":59},[1641],{"nctId":1541,"briefTitle":1542,"status":326,"phases":1642,"primaryCompletion":1544,"completion":1545,"start":1546,"enrollment":1547,"conditions":1643,"interventions":1644},[],[19],[1526,1550,1551,1552,1553,1554],{"intervention":1341,"totalTrials":55,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1648,"activeCount":59},[],{"trials":1650,"activeCount":59},[],{"trials":1652,"activeCount":59},[],{"trials":1654,"activeCount":59},[],{"trials":1656,"activeCount":59},[],{"trials":1658,"activeCount":59},[1659],{"nctId":1660,"briefTitle":1661,"status":176,"phases":1662,"primaryCompletion":1216,"completion":1216,"start":1663,"enrollment":205,"conditions":1664,"interventions":1665},"NCT05800288","Effect of Midazolam Bolus on Eleveld and Schnider TCI (Target Controlled Infusion) Models",[],"2023-03-30",[1341,16],[1341],{"intervention":1667,"totalTrials":55,"cells":1668},"Atorvastatin - Cholestyramine - Sitosterol",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1670,"activeCount":59},[],{"trials":1672,"activeCount":59},[],{"trials":1674,"activeCount":59},[],{"trials":1676,"activeCount":59},[],{"trials":1678,"activeCount":59},[],{"trials":1680,"activeCount":59},[1681],{"nctId":1682,"briefTitle":1683,"status":176,"phases":1684,"enrollment":921,"conditions":1685,"interventions":1688},"NCT01053065","The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study",[52],[1686,306,1687],"Symptomatic Carotid Stenosis","Indication for Carotid Endarterectomy",[1667],{"intervention":1690,"totalTrials":55,"cells":1691},"Aminophylline",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1693,"activeCount":59},[],{"trials":1695,"activeCount":59},[],{"trials":1697,"activeCount":59},[],{"trials":1699,"activeCount":59},[],{"trials":1701,"activeCount":59},[],{"trials":1703,"activeCount":59},[1704],{"nctId":1705,"briefTitle":1706,"status":176,"phases":1707,"primaryCompletion":1337,"completion":1338,"start":1708,"enrollment":762,"conditions":1709,"interventions":1710},"NCT06134037","Effects of Aminophylline Bolus on TCI (Target Controlled Infusion) Concentrations at Burst Suppression Occurence",[],"2023-11-12",[16],[1690]]